Search

Your search keyword '"Type 2 diabetes -- Economic aspects"' showing total 222 results
Start Over Descriptor "Type 2 diabetes -- Economic aspects"
222 results on '"Type 2 diabetes -- Economic aspects"'

1. New weight-loss jabs could boost the economy by getting people 'back into work'; It comes after Health Secretary Wes Streeting suggested that weight-loss jabs could be given to unemployed people to help them return to the workplace

Subjects
Eli Lilly and Co., Prime ministers -- Economic aspects, Economic conditions -- Economic aspects, Type 2 diabetes -- Economic aspects, Pharmaceutical industry -- Economic aspects, General interest, News, opinion and commentary, Mounjaro (Medication)
Abstract

Byline: By, David Lynch and Ella Pickover & PA & Sion Morgan New weight-loss jabs could help boost the economy in Britain by getting people 'back into work', the Prime [...]

Published
2024

2. Free weight-loss jabs could be given to unemployed people to get them back into work; The Prime Minister says anti-obesity injections could help boost Britain's economy

Subjects
Eli Lilly and Co., Obesity -- Economic aspects, Prime ministers -- Economic aspects, Type 2 diabetes -- Economic aspects, Weight loss -- Economic aspects, Pharmaceutical industry -- Economic aspects, General interest, News, opinion and commentary, Mounjaro (Medication)
Abstract

Byline: By, David Lynch Ella Pickover and David Hughes & PA & Deanne Blaylock New weight-loss jabs could help boost the economy in Britain by getting people 'back into work', [...]

Published
2024

3. Weight-loss jabs will get Britain working. Streeting to hand obese patients drugs and stop them 'holding back our economy'

Subjects
Drugs -- Planning -- Economic aspects, Type 2 diabetes -- Economic aspects, Weight loss -- Economic aspects, Company business planning, General interest
Abstract

Byline: Laura Donnelly HEALTH EDITOR UNEMPLOYED people will be given weight-loss jabs under Government plans to get them back to work. Wes Streeting has said the new class of medication [...]

Published
2024

4. Findings from Hubert Department of Global Health Update Understanding of Type 2 Diabetes (An Exploratory Analysis of the Cost-effectiveness of Insulin Glargine 300 Units/ml Versus Insulin Glargine 100 Units/ml Over a Lifetime Horizon Using the ...)

Subjects
Sanofi S.A., World health -- Economic aspects, Medical research -- Economic aspects, Medicine, Experimental -- Economic aspects, Diabetes therapy -- Economic aspects, Insulin glargine -- Economic aspects, Insulin -- Economic aspects, Type 2 diabetes -- Economic aspects, Physical fitness -- Economic aspects, Pharmaceutical industry -- Economic aspects, Health
Abstract

2024 APR 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Nutritional and Metabolic Diseases and Conditions - [...]

Published
2024

5. MedStar Health Research Institute Researchers Update Understanding of Type 2 Diabetes (Greater persistence and adherence to basal insulin therapy is associated with lower healthcare utilization and medical costs in patients with type 2 ...)

Subjects
Medical care, Cost of -- Economic aspects, Diabetes therapy -- Economic aspects, Patient compliance -- Economic aspects, Insulin -- Economic aspects, Type 2 diabetes -- Economic aspects, Physical fitness -- Economic aspects, Health
Abstract

2024 MAR 23 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on type 2 diabetes. According to news reporting [...]

Published
2024

6. Ozempic’s trillion-dollar fiscal threat

Subjects
Weight reducing preparations -- Economic aspects, Type 2 diabetes -- Economic aspects, Weight loss -- Economic aspects, Health insurance -- Economic aspects, Ozempic (Medication)
Abstract

Brian Deese, Jonathan Gruber, and Ryan Cummings The New York Times Ozempic isn’t just a “miracle weight-loss drug,” said Brian Deese, Jonathan Gruber, and Ryan Cummings. It’s “also a major [...]

Published
2024

7. Cigna Healthcare Announces 2025 Marketplace Plans, Offering Quality, Affordable Health Care

Subjects
CIGNA Corp., Medical law -- Economic aspects, Medical care -- Quality management, Type 2 diabetes -- Economic aspects, Health insurance -- Economic aspects, Business, international
Abstract

Bloomfield: Cigna Corp. (CI) has issued the following press release: Cigna Healthcare will provide affordable, comprehensive health care plans in 11 states through the individual marketplace in 2025, marking the [...]

Published
2024

8. AHEAD OF NOVO NORDISK HEARING, 250 CLINICIANS DEMAND AFFORDABLE ACCESS TO OZEMPIC AND WEGOVY

Subjects
Novo Nordisk A/S, Eli Lilly and Co., Type 2 diabetes -- Economic aspects, Medical personnel -- Economic aspects, News, opinion and commentary, Ozempic (Medication), Wegovy (Medication)
Abstract

WASHINGTON -- The following information was released by Vermont Senator Bernie Sanders: Physicians and health professionals from around the country demanded that Novo Nordisk and Eli Lilly make their novel [...]

Published
2024

10. Every day 'a struggle' for former musician battling cancer as energy costs soar; Keith Powell who lives in Warwickshire suffers from multiple illnesses from bladder cancer, type 2 diabetes and arthritis

Subjects
Diseases -- United Kingdom, Bladder cancer -- Economic aspects, Arthritis -- Economic aspects, Charities -- Economic aspects, Type 2 diabetes -- Economic aspects, Musicians -- Economic aspects, General interest, News, opinion and commentary
Abstract

Byline: By, Priyanka Patel A former musician who suffers from multiple medical conditions says that every day is a 'struggle' due to high energy costs. Keith Powell, 81, born in [...]

Published
2024

11. IN HAMILTON, TESTER HIGHLIGHTS COST SAVINGS FOR MONTANANS ON LIFESAVING PRESCRIPTION DRUGS

Subjects
Medicare -- Economic aspects, Medical economics -- Economic aspects, Drugs -- Prescribing -- Economic aspects, Health care industry -- Economic aspects, Type 2 diabetes -- Economic aspects, Health care industry, News, opinion and commentary
Abstract

WASHINGTON -- The following information was released by Montana Senator Jon Tester: U.S. Senator Jon Tester today spoke alongside seniors and local health care providers in Hamilton about the cost-savings [...]

Published
2024

12. Canada : B.C.s biosimilar initiative saves money, reinvests to expand drug coverage

Subjects
Dapagliflozin -- Economic aspects, Prescription drug plans -- Economic aspects, Type 2 diabetes -- Economic aspects, Business, international
Abstract

People in B.C. continue to benefit from the Provinces biosimilars initiative as cost savings increase and are reinvested into BC PharmaCare to further improve access to drug coverage. We are [...]

Published
2024

16. Diabetes care is now more accessible and affordable in India with off patented drugs like SGLT2i: Dr Rajiv Kovil

Subjects
Diabetes therapy -- Economic aspects, Liver -- Economic aspects, Type 2 diabetes -- Economic aspects, Pharmaceuticals and cosmetics industries
Abstract

Byline: Shardul Nautiyal Diabetes care is now more accessible and affordable in India with off patented drugs like sodium--glucose cotransporter 2 (SGLT2), said Dr. Rajiv Kovil, senior diabetologist and co-organising [...]

Published
2023

17. Digbi Health Selected by State Public Health Insurance Trust to Manage Obesity Treatment Costs Amid Escalating GLP-1 Drug Expenses

Subjects
Obesity -- Economic aspects, Chronic diseases -- Economic aspects, Drugs -- Economic aspects, Public health -- Economic aspects, Type 2 diabetes -- Economic aspects, Company business management, Health care industry
Abstract

2024 AUG 27 (NewsRx) -- By a News Reporter-Staff News Editor at Managed Care Business Week -- Digbi Health, a leader in Precision Biology for obesity and chronic disease management, [...]

Published
2024

18. Findings from Wake Forest University Update Knowledge of Obesity and Diabetes (Cross-sectional and Longitudinal Associations Among Healthcare Costs and Deficit Accumulation)

Subjects
United States. National Institute on Aging, Medical care, Cost of -- Economic aspects, Type 2 diabetes -- Economic aspects, Health, Wake Forest University
Abstract

2024 JUL 29 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity & Diabetes Week -- Investigators publish new report on Nutritional and Metabolic Diseases and Conditions - Obesity [...]

Published
2024

19. Findings on Diabetes Research Reported by Investigators at University of York (Estimation of the Direct Health and Indirect Societal Costs of Diabetes In the Uk Using a Cost of Illness Model)

Subjects
Medical care, Cost of -- Economic aspects, Diseases -- United Kingdom, Type 2 diabetes -- Economic aspects, Health, University of York
Abstract

2024 JUL 19 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Diabetes Research have been published. According to news reporting [...]

Published
2024

20. RxConnected Brings Affordable Medications and Fast Delivery to Americans

Subjects
Diabetes therapy -- Economic aspects, Drugs -- Prescribing, Americans -- Economic aspects, Hypoglycemic agents -- Economic aspects, Apixaban -- Economic aspects, Type 2 diabetes -- Economic aspects, General interest, News, opinion and commentary
Abstract

RICHMOND, BC: RxConnected has issued the following news release: RxConnected introduces affordable prices on critical prescription medications to assist Americans with the high cost of treatment. RxConnected's intuitive online platform [...]

Published
2024

21. Lord McColl of Dulwich ask His Majesty's Government what is the total cost of treating patients who are obese and overweight; and what are the associated costs of treating (1) type 2 diabetes, (2) cardiovascular disease, (3) cerebrovascular disease

Subjects
Medical care, Cost of -- Economic aspects, Coronary heart disease -- Economic aspects, Endometrial cancer -- Economic aspects, Colorectal cancer -- Economic aspects, Type 2 diabetes -- Economic aspects, Osteoarthritis -- Economic aspects, Ovarian cancer -- Economic aspects, Pancreatic cancer -- Economic aspects, Business, international
Abstract

London: UK Parliament has issued the following written answer: Answer Lord Markham Answered on 17 May 2024 The department has reviewed and uses cost estimates published by Frontier Economics in [...]

Published
2024

22. AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio

Subjects
Patient compliance -- Economic aspects, Respiratory agents -- Economic aspects, Type 2 diabetes -- Economic aspects, Asthma -- Economic aspects, Business, Business, international, Airsupra (Medication), Symbicort (Medication), Bevespi Aerosphere (Medication)
Abstract

Expanded savings programs build on company's longstanding commitment to addressing barriers to access and affordability for patients WILMINGTON, Del. -- AstraZeneca announced it will expand the savings programs for its [...]

Published
2024

23. FAIR Health Consumer Website Analytics Reveal Consumers' Interest in Better Understanding Out-of-Pocket Costs and Coverage

Subjects
Implant dentures -- Economic aspects, Medical care, Cost of -- Economic aspects, Emergency medical services -- Achievements and awards, Web sites -- Economic aspects, Type 2 diabetes -- Economic aspects, Company Web site/Web page, Business, News, opinion and commentary
Abstract

Visitors to the Site in 2023 Frequently Searched Cost Information for Radiology and Emergency Medical Services Dental Implants and Orthodontic Care Topped List of Most Searched Dental Terms NEW YORK, [...]

Published
2024

24. Why the obesity crisis threatens the world's financial stability; Excess weight is on track to drain more than trillions of pounds from the global economy by 2035

Subjects
Medical care, Cost of -- Economic aspects, Obesity -- Economic aspects, Global economy -- Economic aspects, Type 2 diabetes -- Economic aspects, General interest, News, opinion and commentary
Abstract

Byline: Rachel Batterham The economic impact of obesity and excess weight is fast approaching £98 billion, nearly four per cent of GDP. It is surging to become a significant threat [...]

Published
2024

25. Incretin Mimetic Drugs Overtake Insulin in Total Prescriptions and Costs for Commercially Insured Patients

Subjects
Diabetes therapy -- Economic aspects, Drugs -- Prescribing, Insulin -- Economic aspects, Type 2 diabetes -- Economic aspects, Business, Business, international
Abstract

Cedar Gate's proprietary national Healthcare Benchmark Database reveals important trends in diabetes prescriptions GREENWICH, Conn. -- An analysis by Cedar Gate Technologies found that incretin mimetic prescription medications (also known [...]

Published
2024

26. Slim Pickings: Finding Cost-Effective Obesity Solutions

Subjects
Obesity -- Economic aspects, Liraglutide -- Economic aspects, Type 2 diabetes -- Economic aspects, Telecommunications industry
Abstract

(PRWeb) - The industrial revolution produced cheap, abundant food but combined with lower levels of activity in the modern world we now face an epidemic of obesity. The immense cost [...]

Published
2024

27. EVALUATION OF A DISTRIBUTION MODEL TO INCREASE ACCESS TO AFFORDABLE FRUITS AND VEGETABLES

Subjects
Fruit -- Economic aspects, Vegetables -- Economic aspects, Community supported agriculture -- Economic aspects, Type 2 diabetes -- Economic aspects, News, opinion and commentary
Abstract

ATLANTA, GA -- The following information was released by the Centers for Disease Control and Prevention (CDC): What is already known on this topic? Distribution of reduced-cost or no-cost produce [...]

Published
2024

28. Virta Expands its Provider-led Weight Loss Program to Adults with BMI >25 As Demand Surges for Cost Effective Alternatives to GLP-1 Drugs

Subjects
Weight loss maintenance -- Economic aspects, Diabetes therapy -- Economic aspects, Prediabetic state -- Economic aspects, Type 2 diabetes -- Economic aspects, Weight loss -- Economic aspects, Weight loss industry -- Economic aspects, Business, Business, international
Abstract

Virta Health delivers sustained weight loss results, both as a standalone drug-free treatment, or as an off-ramp to costly GLP-1s like Ozempic, Wegovy, and Mounjaro DENVER -- Virta Health, the [...]

Published
2024

29. Global health and environmental costs of food industry are $10tn a year -- UN; 'Price tag' of non-communicable diseases, malnutrition, poverty and harm to planet is 10% of global GDP, says UN food agency

Subjects
World health -- Economic aspects, Heart diseases -- Economic aspects, Medical care, Cost of -- Economic aspects, Communicable diseases -- Economic aspects, Food industry -- Economic aspects, Agricultural societies -- Economic aspects, Type 2 diabetes -- Economic aspects, Food and beverage production/distribution software, News, opinion and commentary
Abstract

Byline: Weronika Strzyzynska The health and environmental damage caused by food production costs the world $10tn (£8tn) a year, or 10% of global GDP, the UN said. Conditions such as [...]

Published
2023

30. Real savings on life-saving medications coming soon

Subjects
Drugs -- Prescribing -- Economic aspects, Type 2 diabetes -- Economic aspects, Health insurance -- Economic aspects, News, opinion and commentary
Abstract

Byline: Guest Opinion I spend roughly over $400 per month out of pocket on my prescription drugs, which are critical to my health. I am a retired school bus driver [...]

Published
2023

31. Blue Cross and Blue Shield of Minnesota expands no-cost access to Diabetes Prevention Programs, starting in 2024

Subjects
United States. Centers for Disease Control and Prevention, Blue Cross and Blue Shield of Minnesota, Health insurance industry -- Economic aspects, Type 2 diabetes -- Economic aspects, General interest, News, opinion and commentary
Abstract

EAGAN: Blue Cross and Blue Shield of Minnesota has issued the following news release: Blue Cross and Blue Shield of Minnesota (Blue Cross) today announced it is eliminating member cost-sharing [...]

Published
2023

32. Blue Cross and Blue Shield of Minnesota expands no-cost access to Diabetes Prevention Programs, starting in 2024

Subjects
Blue Cross and Blue Shield of Minnesota, Blue Cross and Blue Shield Association, Prediabetic state -- Economic aspects, Type 2 diabetes -- Economic aspects, Business, News, opinion and commentary
Abstract

Evidence-based lifestyle change programs now free for more members with prediabetes or at risk for type 2 diabetes EAGAN, Minn., Nov. 8, 2023 /PRNewswire/ -- Blue Cross and Blue Shield [...]

Published
2023

33. Blue Cross and Blue Shield of Minnesota expands no-cost access to Diabetes Prevention Programs, starting in 2024

Subjects
United States. Centers for Disease Control and Prevention, Blue Cross and Blue Shield of Minnesota, Blue Cross and Blue Shield Association, Health insurance industry -- Economic aspects, Diabetes therapy -- Economic aspects, Stress management -- Economic aspects, Type 2 diabetes -- Economic aspects, Business, international
Abstract

Blue Cross and Blue Shield of Minnesota (Blue Cross) has announced that it will eliminate member cost-sharing for diabetes prevention programs (DPPs) for fully-insured commercial members starting in 2024. This [...]

Published
2023

34. ON THE FIRST DAY OF NATIONAL DIABETES MONTH, GRASSROOTS ORGANIZATIONS ENDORSE SENATOR REVEREND WARNOCK'S BIPARTISAN $35 INSULIN COST CAP

Subjects
Societies -- Economic aspects, Diabetes therapy -- Economic aspects, Insulin -- Economic aspects, Type 2 diabetes -- Economic aspects, Associations, institutions, etc. -- Economic aspects, News, opinion and commentary
Abstract

WASHINGTON -- The following information was released by Georgia Senator Reverend Raphael Warnock: November is National Diabetes Month, which raises awareness about efforts to prevent, treat, and manage theáchronicácondition In [...]

Published
2023

36. Oscar Health, Inc. Announces 2024 Market Expansion Plans, Offering Affordable, Accessible, and Technology-Enabled Care for the Eleventh Consecutive Year

Subjects
Lung diseases, Obstructive -- Economic aspects, Type 2 diabetes -- Economic aspects, Business, Business, international
Abstract

* Major expansion in 165 new markets in 13 states through its Individual & Family Plans * Personalized plans for Chronic Obstructive Pulmonary Disease (COPD), asthma, and diabetes members * [...]

Published
2023

37. Weight-loss drugs will transform our economy as well as our waistlines; The slimming jab revolution is on course to trump AI as this decade's biggest breakthrough

Subjects
Drugs -- Innovations, Type 2 diabetes -- Economic aspects, Weight loss -- Economic aspects, General interest, News, opinion and commentary
Abstract

Byline: Matthew Lynn It will replace hundreds of millions of jobs. It will revolutionise the way we work. And it will turn every major industry upside down. There has been [...]

Published
2023

38. Studies from University of Michigan Provide New Data on Type 2 Diabetes (Cost and Utilization of Healthcare Services for Persons With Diabetes)

Subjects
United States. National Institutes of Health, Medical care -- Utilization, Medical research -- Economic aspects, Medicine, Experimental -- Economic aspects, Medical care, Cost of -- Economic aspects, Type 1 diabetes -- Economic aspects, Type 2 diabetes -- Economic aspects, Health, University of Michigan
Abstract

2024 JAN 1 (NewsRx) -- By a News Reporter-Staff News Editor at Diabetes Week -- Researchers detail new data in Nutritional and Metabolic Diseases and Conditions - Type 2 Diabetes. [...]

Published
2024

40. Massive cost of obesity to the NHS is revealed. Heaviest patients require spending of PS1,400 a year, twice the total for those of healthy weight Government 'failing' on obesity, says charity

Subjects
Medical care, Cost of -- Economic aspects, Obesity -- Economic aspects, Body weight -- Economic aspects, Charities -- Economic aspects, Type 2 diabetes -- Economic aspects, General interest
Abstract

Byline: Laura Donnelly HealtH editor in Dublin OBESE patients cost the NHS twice as much as those of healthy weight, as research shows that the heaviest require PS1,375 of spending [...]

Published
2023

41. A Century After the First Insulin Injection, It's Time to Make Sure It's Affordable

Subjects
Medical centers -- Economic aspects, Diabetes therapy -- Economic aspects, Continuing medical education -- Economic aspects, Insulin -- Economic aspects, College teachers -- Economic aspects, Type 2 diabetes -- Economic aspects, Consumer news and advice, General interest, Harvard University. Harvard Medical School
Abstract

Martin Abrahamson, MD, FACP is an Associate Professor of Medicine at Harvard Medical School and previous Chief Medical Officer at Joslin Diabetes Center. Sanjiv Chopra, MD, MACP, FRCP is a [...]

Published
2022

42. Blue Cross: Benefits of Integrating Medical and Pharmacy Coverage Include Greater Savings, Fewer Trips to the Hospital and ER

Subjects
Blue Cross and Blue Shield of Minnesota, Blue Cross and Blue Shield Association, Health insurance industry -- Economic aspects, Medical care, Cost of -- Economic aspects, Type 2 diabetes -- Economic aspects, Business, international
Abstract

New research provided by Blue Cross and Blue Shield of Minnesota highlights cost and health advantages for employer-based plans. Benefits of integrating medical and pharmacy benefits can generate an average [...]

Published
2023

43. Real-world analysis of GLP-1a drugs for weight loss finds low adherence and increased cost in first year

Subjects
Medical care, Cost of -- Economic aspects, Diabetes therapy -- Economic aspects, Drugs -- Economic aspects, Type 2 diabetes -- Economic aspects, Weight loss -- Economic aspects, General interest, News, opinion and commentary
Abstract

EAGAN: Prime Therapeutics LLC has issued the following news release: An analysis of real-world integrated pharmacy and medical claims data by leading pharmacy benefit manager (PBM) Prime Therapeutics LLC (Prime), [...]

Published
2023

44. Cost-Effectiveness of Advanced Practice Nurses Compared to Physician-Led Care for Chronic Diseases: A Systematic Review

Author

Abraham, Cilgy M., Norful, Allison A., Stone, Patricia W., and Poghosyan, Lusine

Subjects
United States. Centers for Disease Control and Prevention -- International economic relations, Chronic diseases -- Economic aspects, Health care costs -- Economic aspects, Type 2 diabetes -- Economic aspects, Medical care quality -- Economic aspects, Registered nurses -- Economic aspects, Death, Nurses, Medical economics, Disabilities, Public health, Health
Abstract

Globally, advanced practice nurses (APNs) provide high-quality chronic disease care to patients, yet the cost-effectiveness of their services is minimally explored. This review aims to determine the cost-effectiveness of chronic [...]

Published
2019

45. TYPE 2 DIABETES: The costs and benefits of SGLT2 inhibitors & GLP-1 RAs

Author

Dotinga, Randy and Lennon, Katie

Subjects
Empagliflozin -- Economic aspects, Glucose -- Economic aspects, Hypoglycemic agents -- Economic aspects, Type 2 diabetes -- Economic aspects, Diabetes therapy -- Economic aspects, Weight loss -- Economic aspects, Semaglutide -- Economic aspects, Saxagliptin, Peptides, Drugs, Alogliptin, Dapagliflozin, Sitagliptin, Retirement benefits, Insulin, Health, Health care industry
Abstract

The options for treating type 2 diabetes without insulin have grown beyond metformin to include a long list of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagonlike peptide--1 (GLP-1) receptor agonists [...]

Published
2019

46. TYPE 2 DIABETES: The costs and benefits of SGLT2 inhibitors & GLP-1 RAs

Author

Dotinga, Randy and Lennon, Katie

Subjects
Empagliflozin -- Economic aspects, Glucose -- Economic aspects, Hypoglycemic agents -- Economic aspects, Type 2 diabetes -- Economic aspects, Diabetes therapy -- Economic aspects, Weight loss -- Economic aspects, Semaglutide -- Economic aspects, Saxagliptin, Peptides, Drugs, Alogliptin, Dapagliflozin, Sitagliptin, Retirement benefits, Insulin, Health
Abstract

The options for treating type 2 diabetes without insulin have grown beyond metformin to include a long list of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagonlike peptide-1 (GLP-1) receptor agonists [...]

Published
2019

47. 4 Myths of Health Care Cost Reduction

Author

Burjek, Andie

Subjects
Health care costs -- Economic aspects, Type 2 diabetes -- Economic aspects, Employers -- Economic aspects, Medical economics, Loch Ness monster, Business, Human resources and labor relations
Abstract

Employers are doing everything they can to curb health care costs. Sure, and if you believe that you may also believe in unicorns, the Loch Ness monster and Bigfoot roaming [...]

Published
2019

48. Mercer Exec: Employers Are Extremely Concerned About Cost

Author

Plescia, Marissa

Subjects
Medical care, Cost of -- Economic aspects, Employers -- Economic aspects, Diabetes therapy -- Economic aspects, Pharmacy -- Economic aspects, Type 2 diabetes -- Economic aspects
Abstract

https://medcitynews.com/2023/10/mercer-employers-health-costs/ Cancer and pharmacy services are driving up costs for employers. One Mercer exec recently laid out several recommendations for employers to manage these costs. https://medcitynews.com/uploads/2021/05/GettyImages-1151185443-300x200.jpg Employers have a long [...]

Published
2023

49. Ghent University Researchers Update Current Study Findings on Hypertension (Cost effectiveness review of text messaging, smartphone application, and website interventions targeting T2DM or hypertension)

Subjects
Diabetes therapy -- Economic aspects, Text messaging -- Economic aspects, Smart phones -- Economic aspects, Web sites -- Economic aspects, Type 2 diabetes -- Economic aspects, Hypertension -- Economic aspects, Smart phone, Company Web site/Web page, Text messaging, Health
Abstract

2023 SEP 8 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Researchers detail new data in hypertension. According to news originating from Ghent University [...]

Published
2023

50. Capping insulin costs

Author

Milligan, Susan

Subjects
Diabetes therapy -- Economic aspects, Insulin -- Economic aspects, Type 2 diabetes -- Economic aspects, General interest
Abstract

West Virginians who use insulin will see their copays for the diabetes drug capped at $35 a month in aggregate under a state law that will take effect Jan. 1. [...]

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results